VINORELBINE PIERRE FABRE vinorelbine 10mg/mL (as tartrate) injection vial

País: Austràlia

Idioma: anglès

Font: Department of Health (Therapeutic Goods Administration)

ingredients actius:

vinorelbine tartrate, Quantity: 13.85 mg/mL (Equivalent: vinorelbine, Qty 10 mg/mL)

Disponible des:

Pierre Fabre Australia Pty Ltd

formulario farmacéutico:

Injection, concentrated

Composición:

Excipient Ingredients: water for injections

Vía de administración:

Intravenous

Unidades en paquete:

10 x 1ML, 1 x 1mL

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Vinorelbine Pierre Fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. Vinorelbine Pierre Fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage IB or greater.

Resumen del producto:

Visual Identification: A clear, colourless to pale yellow solution; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Estat d'Autorització:

Licence status A

Data d'autorització:

2000-08-04